Table 5.
Odds ratios and their confidence intervals for clinical status and CCL4 genotypic frequencies in breast cancer subtypes.
| Variable | Luminal A + Luminal B N=220 (%) |
HER2 overexpression + TNBC N=94 (%) |
|||||
|---|---|---|---|---|---|---|---|
| Clinical Stage | Clinical Stage | ||||||
| Stage I/II | Stage III/IV | OR (95% CI) | Stage I/II | Stage III/IV | OR (95% CI) | ||
| rs10491121 | |||||||
| AA | 40 (72.7) | 15 (27.3) | 1.00 (reference) | 19 (79.2) | 5 (20.8) | 1.00 (reference) | |
| AG | 93 (85.3) | 16 (14.7) | 0.459 (0.207-1.017) | 27 (62.8) | 16 (37.2) | 2.252 (0.704-7.206) | |
| GG | 40 (71.4) | 16 (28.6) | 1.067 (0.465-2.445) | 23 (85.2) | 4 (14.8) | 0.661 (0.155-2.813) | |
| AG+GG | 133 (80.6) | 32 (19.4) | 0.642 (0.316-1.302) | 50 (71.4) | 20 (28.6) | 1.52 (0.499-4.627) | |
| rs1634507 | |||||||
| GG | 77 (78.6) | 21 (21.4) | 1.00 (reference) | 29 (78.4) | 8 (21.6) | 1.00 (reference) | |
| GT | 74 (77.9) | 21 (22.1) | 1.041 (0.525-2.062) | 28 (65.1) | 15 (34.9) | 1.942 (0.712-5.294) | |
| TT | 22 (81.5) | 5 (18.5) | 0.833 (0.282-2.464) | 12 (85.7) | 2 (14.3) | 0.604 (0.112-3.272) | |
| GT+TT | 96 (78.7) | 26 (21.3) | 0.993 (0.519-1.899) | 40 (70.2) | 17 (29.8) | 1.541 (0.586-4.051) | |
| rs1719153 | |||||||
| AA | 85 (78) | 24 (22) | 1.00 (reference) | 32 (80) | 8 (20) | 1.00 (reference) | |
| AT | 74 (78.7) | 20 (21.3) | 0.957 (0.49-1.871) | 25 (62.5) | 15 (37.5) | 2.4 (0.879-6.556) | |
| TT | 14 (82.4) | 3 (17.6) | 0.759 (0.201-2.86) | 12 (85.7) | 2 (14.3) | 0.667 (0.124-3.597) | |
| AT+TT | 88 (79.3) | 23 (20.7) | 0.926 (0.486-1.764) | 37 (68.5) | 17 (31.5) | 1.838 (0.701-4.821) | |
| Tumor size | Tumor size | ||||||
| ≤T2 | >T2 | OR (95% CI) | ≤T2 | >T2 | OR (95% CI) | ||
| rs10491121 | |||||||
| AA | 53 (96.4) | 2 (3.6) | 1.00 (reference) | 23 (95.8) | 1 (4.2) | 1.00 (reference) | |
| AG | 106 (97.2) | 3 (2.8) | 0.75 (0.122-4.626) | 38 (88.4) | 5 (11.6) | 3.026 (0.332-27.548) | |
| GG | 54 (96.4) | 2 (3.6) | 0.981 (0.133-7.225) | 24 (88.9) | 3 (11.1) | 2.875 (0.279-29.677) | |
| AG+GG | 160 (97) | 5 (3) | 0.828 (0.156-4.395) | 62 (88.6) | 8 (11.4) | 2.968 (0.352-25.054) | |
| rs1634507 | |||||||
| GG | 95 (96.9) | 3 (3.1) | 1.00 (reference) | 35 (94.6) | 2 (5.4) | 1.00 (reference) | |
| GT | 92 (96.8) | 3 (3.2) | 1.033 (0.203-5.248) | 37 (86) | 6 (14) | 2.838 (0.537-15.01) | |
| TT | 26 (96.3) | 1 (3.7) | 1.218 (0.122-12.201) | 13 (92.9) | 1 (7.1) | 1.346 (0.112-16.13) | |
| GT+TT | 118 (96.7) | 4 (3.3) | 1.073 (0.235-4.914) | 50 (87.7) | 7 (12.3) | 2.45 (0.48-12.501) | |
| rs1719153 | |||||||
| AA | 106 (97.2) | 3 (2.8) | 1.00 (reference) | 38 (95) | 2 (5) | 1.00 (reference) | |
| AT | 91 (96.8) | 3 (3.2) | 1.165 (0.229-5.913) | 34 (85) | 6 (15) | 3.353 (0.634-17.738) | |
| TT | 16 (94.1) | 1 (5.9) | 2.208 (0.216-22.548) | 13 (92.9) | 1 (7.1) | 1.462 (0.122-17.482) | |
| AT+TT | 107 (96.4) | 4 (3.6) | 1.321 (0.289-6.044) | 47 (87) | 7 (13) | 2.83 (0.555-14.423) | |
| Lymph node status | Lymph node status | ||||||
| N0+N1 | N2+N3 | OR (95% CI) | N0+N1 | N2+N3 | OR (95% CI) | ||
| rs10491121 | |||||||
| AA | 46 (83.6) | 9 (16.4) | 1.00 (reference) | 22 (91.7) | 2 (8.3) | 1.00 (reference) | |
| AG | 103 (94.5) | 6 (5.5) | 0.298 (0.1-0.885)* | 37 (86) | 6 (14) | 1.784 (0.331-9.619) | |
| GG | 48 (85.7) | 8 (14.3) | 0.852 (0.303-2.397) | 27 (100) | 0 (0) | 0.917 (0.813-1.034) | |
| AG+GG | 151 (91.5) | 14 (8.5) | 0.474 (0.193-1.166) | 64 (91.4) | 6 (8.6) | 1.031 (0.194-5.489) | |
| rs1634507 | |||||||
| GG | 87 (88.8) | 11 (11.2) | 1.00 (reference) | 34 (91.9) | 3 (8.1) | 1.00 (reference) | |
| GT | 87 (91.6) | 8 (8.4) | 0.727 (0.279-1.896) | 38 (88.4) | 5 (11.6) | 1.491 (0.331-6.712) | |
| TT | 23 (85.2) | 4 (14.8) | 1.375 (0.401-4.721) | 14 (100) | 0 (0) | 0.919 (0.835-1.011) | |
| GT+TT | 110 (90.2) | 23 (10.5) | 0.863 (0.363-2.049) | 52 (91.2) | 5 (8.8) | 1.09 (0.244-4.861) | |
| rs1719153 | |||||||
| AA | 99 (90.8) | 10 (9.2) | 1.00 (reference) | 37 (92.5) | 3 (7.5) | 1.00 (reference) | |
| AT | 84 (89.4) | 10 (10.6) | 1.179 (0.468-2.968) | 35 (87.5) | 5 (12.5) | 1.762 (0.392-7.929) | |
| TT | 14 (82.4) | 3 (17.6) | 2.121 (0.52-8.658) | 14 (100) | 0 (0) | 0.925 (0.847-1.01) | |
| AT+TT | 98 (88.3) | 13 (11.7) | 1.313 (0.55-3.136) | 49 (90.7) | 5 (9.3) | 1.259 (0.283-5.605) | |
| Distant metastasis | Distant metastasis | ||||||
| M0 | M1 | OR (95% CI) | M0 | M1 | OR (95% CI) | ||
| rs10491121 | |||||||
| AA | 52 (94.5) | 3 (5.5) | 1.00 (reference) | 22 (91.7) | 2 (8.3) | 1.00 (reference) | |
| AG | 109 (100) | 0 (0) | 0.945 (0.887-1.007)* | 40 (93) | 3 (7) | 0.825 (0.128-5.317) | |
| GG | 55 (98.2) | 1 (1.8) | 0.315 (0.032-3.127) | 26 (96.3) | 1 (3.7) | 0.423 (0.036-4.985) | |
| AG+GG | 164 (99.4) | 1 (0.6) | 0.106 (0.011-1.038)* | 66 (94.3) | 4 (5.7) | 0.667 (0.114-3.893) | |
| rs1634507 | |||||||
| GG | 95 (96.9) | 3 (3.1) | 1.00 (reference) | 35 (94.6) | 2 (5.4) | 1.00 (reference) | |
| GT | 95 (100) | 0 (0) | 0.969 (0.936-1.004) | 39 (90.7) | 4 (9.3) | 1.795 (0.31-10.408) | |
| TT | 26 (96.3) | 1 (3.7) | 1.218 (0.122-12.201) | 14 (100) | 0 (0) | 0.946 (0.876-1.022) | |
| GT+TT | 121 (99.2) | 1 (0.8) | 0.262 (0.027-2.556) | 53 (93) | 4 (7) | 1.321 (0.229-7.602) | |
| rs1719153 | |||||||
| AA | 106 (97.2) | 3 (2.8) | 1.00 (reference) | 38 (95) | 2 (5) | 1.00 (reference) | |
| AT | 94 (100) | 0 (0) | 0.972 (0.942-1.004) | 36 (90) | 4 (10) | 2.111 (0.364-12.24) | |
| TT | 16 (94.1) | 1 (5.9) | 2.208 (0.216-22.548) | 14 (100) | 0 (0) | 0.95 (0.885-1.02) | |
| AT+TT | 110 (99.1) | 1 (0.9) | 0.321 (0.033-3.137) | 50 (92.6) | 4 (7.4) | 1.52 (0.264-8.738) | |
| Histological grade | Histological grade | ||||||
| G1+G2 | G3+G4 | OR (95% CI) | G1+G2 | G3+G4 | OR (95% CI) | ||
| rs10491121 | |||||||
| AA | 45 (81.8) | 10 (18.2) | 1.00 (reference) | 13 (54.2) | 11 (45.8) | 1.00 (reference) | |
| AG | 95 (87.2) | 14 (12.8) | 0.663 (0.274-1.608) | 16 (37.2) | 27 (62.8) | 1.994 (0.724-5.495) | |
| GG | 40 (71.4) | 16 (28.6) | 1.8 (0.734-4.417) | 9 (33.3) | 18 (66.7) | 2.364 (0.761-7.343) | |
| AG+GG | 135 (81.8) | 30 (18.2) | 1 (0.453-2.206) | 25 (35.7) | 45 (64.3) | 2.127 (0.831-5.446) | |
| rs1634507 | |||||||
| GG | 81 (82.7) | 17 (17.3) | 1.00 (reference) | 18 (48.6) | 19 (51.4) | 1.00 (reference) | |
| GT | 81 (85.3) | 14 (14.7) | 0.824 (0.381-1.781) | 16 (37.2) | 27 (62.8) | 1.599 (0.654-3.906) | |
| TT | 18 (66.7) | 9 (33.3) | 2.382 (0.916-6.196) | 4 (28.6) | 10 (71.4) | 2.368 (0.628-8.926) | |
| GT+TT | 99 (81.1) | 23 (18.9) | 1.107 (0.554-2.212) | 20 (35.1) | 37 (64.9) | 1.753 (0.754-4.074) | |
| rs1719153 | |||||||
| AA | 90 (82.6) | 19 (17.4) | 1.00 (reference) | 19 (47.5) | 21 (52.5) | 1.00 (reference) | |
| AT | 80 (85.1) | 14 (14.9) | 0.829 (0.39-1.76) | 13 (32.5) | 27 (67.5) | 1.879 (0.759-4.655) | |
| TT | 10 (58.8) | 7 (41.2) | 3.316 (1.12-9.815)* | 6 (42.9) | 8 (57.1) | 1.206 (0.354-4.115) | |
| AT+TT | 90 (81.1) | 21 (18.9) | 1.105 (0.557-2.195) | 19 (35.2) | 35 (64.8) | 1.667 (0.723-3.841) | |
The odds ratios (ORs) with their 95% confidence intervals (CIs) were estimated by logistic regression analysis. The adjusted odds ratios (AORs) with their 95% CIs were estimated by multiple logistic regression analysis that controlled for smoking, consumption and age. * p<0.05.
HER2 = human epidermal growth factor receptor 2; TNBC = triple-negative breast cancer; T2 = tumor >20 mm but ≤50 mm in greatest dimension; N0 = lymph node-negative; N1 = cancer has spread to 1-3 lymph node(s); N2 = 4-9 lymph nodes; N3 = ≥10 positive lymph nodes; M0 = noninvasive cancer; M1 = cancer has metastasized to organs or lymph nodes away from the breast; G1 = well differentiated (low grade); G2 = moderately differentiated (intermediate grade); G3 = poorly differentiated (high grade); G4 = undifferentiated (high grade).